KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Current Liabilities (2016 - 2025)

BeOne Medicines (ONC) has disclosed Total Current Liabilities for 11 consecutive years, with $2.4 billion as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 16.94% to $2.4 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 billion, a 16.94% increase, with the full-year FY2024 number at $2.2 billion, up 22.36% from a year prior.
  • Total Current Liabilities was $2.4 billion for Q3 2025 at BeOne Medicines, up from $2.2 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $2.4 billion in Q3 2025 to a low of $917.4 million in Q4 2022.
  • A 5-year average of $1.7 billion and a median of $1.8 billion in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: plummeted 42.65% in 2022, then skyrocketed 97.32% in 2023.
  • BeOne Medicines' Total Current Liabilities stood at $1.6 billion in 2021, then tumbled by 42.65% to $917.4 million in 2022, then surged by 97.32% to $1.8 billion in 2023, then rose by 22.36% to $2.2 billion in 2024, then rose by 6.93% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Total Current Liabilities are $2.4 billion (Q3 2025), $2.2 billion (Q4 2024), and $2.0 billion (Q3 2024).